Anti-Cancer Clinical Compound Library
During the past decades, we have witnessed many landmark discoveries and successes in cancer research and therapy,however, cancer is still a major health problem for human beings, and it often physically and emotionally brings pains and difficulties to those living with it. Cancer cells remain undifferentiated (continue to divide, causing more damage, and invading new tissue), lack normal cell signaling responses (loss of contact inhibition and evasion of programmed cell death), contain abnormal changes (genetic abnormalities) in chromatin, have altered energy metabolism, and induce vascularization (ensure a steady supply of oxygen and nutrients).
We carefully select 1990 anti-cancer compounds currently in clinical trial phases based on published literatures and database to form this collection that can be used for high throughput screening and high content screening.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Product Description
- A unique collection of 1990 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS).
- Bioactivity confirmed by pre-clinical research and all of them are currently in clinical trial phases, representing the cutting-edge treatments for cancers.
- Effective tool for cancer research and drug repurposing screening.
- Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc., in lung cancer, breast cancer, leukemia, lymphoma, etc.
- Detailed compound information with structure, target, activity, IC50 value, and biological activity description.
- Structurally diverse, medicinally active, and cell permeable.
- NMR and HPLC validated to ensure high purity and quality.